Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023.
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Inari Medical Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023.
First Quarter Financial and Recent Business Highlights
- Generated revenue of $116.2 million in the first quarter of 2023, up 7.8% sequentially and 33.9% over the same quarter last year.
- Announced highly positive results from the FLAME study in high-risk/massive pulmonary embolism at the 2023 American College of Cardiology conference.
- Ended the quarter with $328.4 million in cash, cash equivalents and short-term investments.
“Our strong financial performance in the first quarter reflected consistent execution across all of our growth drivers,” said Drew Hykes, CEO of Inari Medical. “We announced positive results from our FLAME study, which we believe will serve to change the standard of care for the treatment of high-risk PE. We also received FDA clearance for several new products that will drive market expansion while further distancing Inari from both existing and future competition. Our commitment to patients has never been stronger.”
First Quarter 2023 Financial Results
Revenue was $116.2 million for the first quarter of 2023, compared to $86.8 million for the first quarter of 2022 and $107.8 million for the prior quarter. The increase over prior periods was driven primarily by continued commercial expansion, increased adoption of our procedures, and introduction of new products.
Gross profit was $102.4 million for the first quarter of 2023, compared to $76.8 million for the same period of 2022. Gross margin was 88.2% for the first quarter of 2023, compared to 88.5% for the same period in the prior year. The slight decrease in gross margin was primarily due to the increase in costs associated with the addition of new components offered under our FlowTriever system price partially offset by manufacturing efficiencies.
Operating expenses for the first quarter of 2023 were $107.8 million, compared to $79.9 million for the first quarter of 2022. The increase was mainly driven by personnel-related expenses, including stock-based compensation, as we increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.
Net loss was $2.2 million for the first quarter of 2023 and net loss per share was $0.04 on a weighted-average basic and diluted share count of 54.8 million, compared to a net loss of $3.1 million and a net loss per share of $0.06 on a weighted-average basic and diluted share count of 51.0 million, in the same period of the prior year.
Full-Year 2023 Revenue Guidance
For the full year 2023, we are revising our revenue guidance to a range of $478 million to $488 million, an increase of $8.0 million from our original guidance range of $470 million to $480 million.
Webcast and Conference Call Information
Inari Medical will host a conference call to discuss the first quarter 2023 financial results after market close on Wednesday, May 3, 2023 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com.
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.
Forward Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2023 revenue and utility of clinical data results, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2022, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
| INARI MEDICAL, INC. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (in thousands, except share and per share data) (unaudited) |
||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | $ | 116,167 | $ | 86,752 | ||||
| Cost of goods sold | 13,741 | 9,967 | ||||||
| Gross profit | 102,426 | 76,785 | ||||||
| Operating expenses | ||||||||
| Research and development | 22,064 | 16,135 | ||||||
| Selling, general and administrative | 85,700 | 63,732 | ||||||
| Total operating expenses | 107,764 | 79,867 | ||||||
| Loss from operations | (5,338 | ) | (3,082 | ) | ||||
| Other income (expense) | ||||||||
| Interest income | 4,145 | 50 | ||||||
| Interest expense | (40 | ) | (73 | ) | ||||
| Other income (expense) | 39 | (24 | ) | |||||
| Total other income (expense) | 4,144 | (47 | ) | |||||
| Loss before income taxes | (1,194 | ) | (3,129 | ) | ||||
| Provision for income taxes | 1,024 | — | ||||||
| Net loss | $ | (2,218 | ) | $ | (3,129 | ) | ||
| Other comprehensive income (loss) | ||||||||
| Foreign currency translation adjustments | 9 | (117 | ) | |||||
| Unrealized loss on available-for-sale debt securities | (865 | ) | (248 | ) | ||||
| Total other comprehensive loss | (856 | ) | (365 | ) | ||||
| Comprehensive loss | $ | (3,074 | ) | $ | (3,494 | ) | ||
| Net loss per share | ||||||||
| Basic | $ | (0.04 | ) | $ | (0.06 | ) | ||
| Diluted | $ | (0.04 | ) | $ | (0.06 | ) | ||
| Weighted average common shares used to compute net loss per share | ||||||||
| Basic | 54,756,024 | 50,954,715 | ||||||
| Diluted | 54,756,024 | 50,954,715 | ||||||
| INARI MEDICAL, INC. Condensed Consolidated Balance Sheets (in thousands, except share data) (unaudited) |
||||||||
| March 31, 2023 |
December 31, 2022 |
|||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 56,562 | $ | 60,222 | ||||
| Short-term investments in debt securities | 271,884 | 266,179 | ||||||
| Accounts receivable, net | 55,719 | 58,611 | ||||||
| Inventories, net | 36,499 | 32,581 | ||||||
| Prepaid expenses and other current assets | 4,942 | 5,312 | ||||||
| Total current assets | 425,606 | 422,905 | ||||||
| Property and equipment, net | 21,245 | 21,655 | ||||||
| Operating lease right-of-use assets | 50,599 | 50,703 | ||||||
| Deposits and other assets | 9,084 | 8,889 | ||||||
| Total assets | $ | 506,534 | $ | 504,152 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 7,352 | $ | 7,659 | ||||
| Payroll-related accruals | 28,443 | 38,955 | ||||||
| Accrued expenses and other current liabilities | 11,018 | 8,249 | ||||||
| Operating lease liabilities, current portion | 1,527 | 1,311 | ||||||
| Total current liabilities | 48,340 | 56,174 | ||||||
| Operating lease liabilities, noncurrent portion | 31,458 | 30,976 | ||||||
| Total liabilities | 79,798 | 87,150 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022 | — | — | ||||||
| Common stock, $0.001 par value, 300,000,000 shares authorized as of March 31, 2023, and December 31, 2022; 57,083,716 and 54,021,656 shares issued and outstanding as of March 31, 2023 and December 31, 2021, respectively | 57 | 54 | ||||||
| Additional paid in capital | 475,754 | 462,949 | ||||||
| Accumulated other comprehensive (loss) income | (7 | ) | 849 | |||||
| Accumulated deficit | (49,068 | ) | (46,850 | ) | ||||
| Total stockholders' equity | 426,736 | 417,002 | ||||||
| Total liabilities and stockholders' equity | $ | 506,534 | $ | 504,152 | ||||
